Premium
Risk of developing diabetes in patients with atrial fibrillation taking non‐vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study
Author(s) -
Huang HueiKai,
Liu Peter PinSung,
Lin ShuMan,
Hsu JinYi,
Peng Carol ChiungHui,
Munir Kashif M.,
Wu TingYu,
Yeh JihI,
Loh ChingHui,
Tu YuKang
Publication year - 2021
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14243
Subject(s) - medicine , warfarin , apixaban , vitamin k antagonist , rivaroxaban , dabigatran , hazard ratio , atrial fibrillation , diabetes mellitus , cohort , confidence interval , retrospective cohort study , cohort study , endocrinology
Aim To compare the risk of diabetes development in patients with atrial fibrillation (AF) treated with non‐vitamin K antagonist oral anticoagulants (NOACs) and warfarin. Materials and Methods We conducted a nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database. Adult patients with new onset of AF, treated with NOACs or warfarin between 2012 and 2016, were included. The NOAC cohort was further divided into dabigatran, rivaroxaban and apixaban groups. The primary outcome was incident diabetes requiring treatment with antidiabetic drugs. Fine and Gray subdistribution hazards models were used to estimate the adjusted hazard ratio (aHR). Propensity score matching was performed for each head‐to‐head comparison. Results A total of 10 746 new‐onset AF patients were included in our study. During the mean 2.4‐year follow‐up, NOACs were associated with a lower risk of developing diabetes than warfarin (aHR = 0.80, 95% confidence interval [CI]: 0.68‐0.94, P = .007). Subgroup analyses confirmed that dabigatran, rivaroxaban and apixaban each had a reduced diabetes risk. Stratified analyses showed that the lower risk of diabetes associated with NOAC treatment was specific to patients aged 65 years or older (aHR = 0.74, 95% CI: 0.62‐0.89, P = .002) and those with good medication adherence (aHR = 0.70, 95% CI: 0.58‐0.84, P < .001). Conclusions Taking an NOAC was associated with a lower risk of developing diabetes than taking warfarin in patients with AF.